We have earlier shown that antisense morpholino oligomers are able to restore dystrophin expression by systemic delivery in body-wide skeletal muscles of dystrophic mdx mice. However, the levels of dystrophin expression vary considerably and, more importantly, no dystrophin expression has been achieved in cardiac muscle. In this study, we investigate the efficiency of morpholino-induced exon skipping in cardiomyoblasts and myocytes in vitro, and in cardiac muscle in vivo by dose escalation. We showed that morpholino induces targeted exon skipping equally effectively in both skeletal muscle myoblasts and cardiomyoblasts. Effective exon skipping was achieved in cardiomyocytes in culture. In the mdx mice, morpholino rescues dystrophin expression dose dependently in both skeletal and cardiac muscles. Therapeutic levels of dystrophin were achieved in cardiac muscle albeit at higher doses than in skeletal muscles. Up to 50 and 30% normal levels of dystrophin were induced by single systemic delivery of 3 g kg -1 of morpholino in skeletal and cardiac muscles, respectively. High doses of morpholino treatment reduced the serum levels of creatine kinase without clear toxicity. These findings suggest that effective rescue of dystrophin in cardiac muscles can be achieved by morpholino for the treatment of Duchenne muscular dystrophy.
Introduction
Duchenne muscular dystrophy (DMD) affects one in approximately 3500 male births and is characterized by rapid progression of muscle degeneration. The disease is caused by nonsense and frame-shift mutations in the DMD gene at Xp21.1, resulting in lack of dystrophin production. 1 In-frame mutations in the dystrophin gene also cause a milder form of Becker muscular dystrophy with expression of truncated but partially functional dystrophin proteins. [2] [3] [4] The amount of dystrophin in Becker muscular dystrophy varies, but can reach 30% or higher of normal levels, in contrast to only a few revertant fibers in the majority of DMD. 5 The DMD gene consists of 79 exons spanning 42.3 million base pairs. The muscle form of dystrophin protein has 3685 amino acids (427 kDa) that can be divided into four structural domains: amino terminal, rod, cysteine-rich and carboxy terminal domains. The majority (approximately 60%) of the DMD mutations occur within the rod domain of dystrophin, which spans about half the length of the protein. However, the rod domain of the dystrophin gene appears not to be critical for its functions. For instance, deletion of exons from 17 to 49 was associated with only a mild clinical phenotype. 6 Similarly, an artificially constructed microdystrophin with deletion from exon 18 to 58 remains largely functional. 7 Antisense oligonucleotide (AON)-mediated exon skipping is able to restore the reading frame of dystrophin gene disrupted by DMD mutations. This can lead to the production of truncated but functional dystrophin, and can reverse a DMD to a milder Becker muscular dystrophy or near normal phenotypes. [8] [9] [10] [11] The therapeutic potential of antisense therapy for DMD was initially showed in the dystrophic mdx mouse that harbors a nonsense point mutation in the exon 23, leading to general absence of dystrophin in the muscles. Specifically designed 2 0 O methyl phosphorothioate AONs delivered by intramuscular injections were able to skip the exon 23 effectively in tibialis anterior (TA) muscles and produce functional amount of proteins. 8 The same 2 0 O methyl phosphorothioate AON was shown to induce dystrophin expression in body-wide muscles when delivered systemically. 9 More recently, regular systemic administration of the phosphorodiamidate morpholino oligomers targeting the same mouse dystrophin exon 23 induced effective exon skipping and produced functional levels of dystrophin in skeletal muscles. 10 Systemic effect of morpholino oligomers for exon skipping has now been shown in dystrophic dog.
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The dog harbors a splice site mutation in intron 6, leading to exclusion of exon 7 from the mRNA transcript. Treating the dogs weekly or biweekly with a cocktail of three morpholino oligomers (120-200 mg kg -1 ) systemically resulted in further removal of exon 6 and 8 with extensive dystrophin expression and significant functional stabilization by several criteria. 11 Furthermore, effective restoration of reading frame and production of dystrophin have now been achieved in Phase I clinical trials targeting human dystrophin exon 51 in muscles of DMD patients by local injections with both 2 0 O methyl phosphorothioate AONs and morpholino oligomers (personal communication). 12, 13 DMD affects body-wide muscles including the cardiac muscle. As DMD patients live longer because of improved multidisciplinary patient care, rescuing dystrophin expression in cardiac muscle becomes more critical for their longevity and quality of life. [14] [15] [16] [17] [18] [19] [20] More importantly, a recent study suggests that restoration of dystrophin in skeletal muscles only may exacerbate the failure of heart function if dystrophin expression cannot be effectively restored in cardiac muscle. 16 However, both unmodified 2 0 O methyl phosphorothioate AONs and morpholino oligomers have been unable to induce effective exon skipping and dystrophin expression in cardiac muscle. This could severely limit the therapeutic values of the treatment to DMD patients with the current chemistries on clinic trials. 12, 13 The mechanism(s) for the lower antisense effect in cardiac muscle is not understood, but one likely contributing factor is the lower delivery efficiency of antisense oligomers to cardiomyocytes than to myofibers in skeletal muscles. 10 In this study, we investigated the efficiency of morpholino-induced exon skipping in cardiomyoblasts and myocytes in vitro, and in cardiac muscles in vivo by dose escalation. Morpholino oligomer (morpholinoE23) was able to induce targeted exon 23 skipping in both skeletal and cardiac myoblasts with similar efficiency. Effective exon skipping was also achieved in freshly isolated cardiomyocytes. In the mdx mice, morpholinoE23 rescued dystrophin expression dose dependently in both skeletal and cardiac muscles. However, potential therapeutic levels of dystrophin were achieved in cardiac muscles at considerable higher dosage than in skeletal muscles. MorpholinoE23 treatment, up to 3 g kg -1 delivered systemically, produced approximately 50 and 30% normal levels of dystrophin in skeletal and cardiac muscles, respectively, without acute and short-term toxicity. Considerable reduction in the serum levels of creatine kinase was detected in mice treated with morpholinoE23 at 0.03 g kg -1 and above. Improved muscle pathology was observed in the diaphragm after treatment with 1.5 g kg -1 or higher dose of morpholinoE23. These findings suggest that effective rescue of dystrophin in cardiac muscles can be achieved by unmodified morpholino with a dose probably tolerable for long-term treatment.
Results

MorpholinoE23 induces skipping of exon 23 efficiently in cardiac myoblast and myocytes
To examine whether cardiac myoblasts and myocytes could be effectively induced to skip dystrophin exon 23, we established cardiac myoblast culture from young mdx mice (2 weeks old) for morpholinoE23 transfection ( Figure 1a ). The nature of cardiac myoblasts was confirmed by immunocytochemistry for Troponin I (Figure 1b) . The cells and C2C12 myoblasts as a control were first incubated with 10 mg ml -1 fluorescein isothiocyanate-labeled morpholino and the delivery was monitored directly under fluorescence microscope. Efficient delivery of the labeled morpholino was clearly demonstrated, as almost all cells showed fluorescence with stronger signal within the nuclear areas (Figure 2a) . The cells were then incubated with morpholinoE23 specific for targeting exon 23 of the mouse dystrophin. Exon skipping was examined 1, 2 and 4 days after treatment. RT-PCR showed targeted skipping of exon 23 in both cell types. Approximately 30 and 50% of exon 23 skipping were observed with 10 and 50 mg ml -1 morpholinoE23 respectively, in both skeletal and cardiac myoblasts (Figure 2b ). Maximum efficiency of exon skipping was observed 4 days after 50 mg ml -1 morpholinoE23 treatment in both types of myoblasts (Figure 2c ).
We also examined exon 23 skipping in freshly prepared cardiomyocytes. Exon 23 skipping was clearly detected 2 days after treatment with 50 mg ml -1 morpholinoE23. As expected, the isolated cardiomyocytes only survived for a limited time in culture and no exon skipping was detected by day 5 after the isolation ( Figure  2d ). These results, therefore, suggest that specific exon skipping can be achieved in cardiac myocytes when effective delivery of morpholino is achieved. 
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To investigate if exon skipping could be more effectively tested using ex vivo tissues from cardiac muscles, freshly isolated heart muscles and TA muscles were incubated with 50 mg ml -1 morpholinoE23 and exon skipping was examined at different time points. No exon skipping was detected by day 2 and 5 after transfection. Only o5% normal levels of RNA were isolated compared with that isolated from the same amount of freshly dissected tissues of both types by day 5 after transfection, consistent with significant degradation of the muscle tissues in culture. However, exon skipping was detected from the morpholinoE23-treated tissues at day 7 with efficiency similar in both types of muscles ( Figure 2d ).
Intravenous injection of morpholinoE23 induced dose-dependent expression of dystrophin in skeletal muscles
We have earlier shown that body-wide dystrophin induction in skeletal muscles can be enhanced by regular systemic injections of 2 mg per adult mdx mouse (approximately 60-80 mg kg -1 bodyweight) morpholinoE23, although considerable variation in dystrophin levels persists. We, therefore, predict that higher dosage might be able to achieve a more homogeneous expression of dystrophin in skeletal muscle. A series of doses, ranging from 0.015 (data not shown), 0.03, 0.06, 0.15, 0.3, 0.6, 1.5 to 3 g kg -1 , were used for single intravenous injections into the mdx mice, and body-wide muscles were examined 2 weeks later. MorpholinoE23 at the doses of 0.06 g kg -1 or below did not induce detectable increase in the number of dystrophin positive fibers and no increase in the dystrophin protein was observed in nearly all muscles examined. Consistently, RT-PCR showed no detectable transcript with targeted exon 23 skipped (data no shown). However, 0.15 g kg -1 morpholinoE23 induced dystrophin expression in 415% fibers of nearly all skeletal muscles, although most of the fibers were only weakly stained by immunohistochemistry ( Figures 3 and 4a ). The number of dystrophin positive fibers reached to 30 and 40% with the doses of 0.3 g and 0.6 g kg -1 , respectively. The signal intensity also increased with the increase in doses, and the amount of dystrophin measured by western blots reached 10-15% of normal levels. However, dystrophin expression remained highly variable within all skeletal muscles examined, and areas of fibers completely lacking dystrophin expression persisted ( Figures 3 and 4) . Levels of dystrophin continued to improve as the dose of morpholinoE23 increased. Nearly all fibers became dystrophin positive in all skeletal muscles examined in the mice treated with 3 g kg -1 , although variation in signal intensity remained. At this dose, the amount of dystrophin protein reached 50% of the normal levels in all skeletal muscles including TA, intercostals, digital muscles, back trapezius, thoracic and lumbar muscles (Figures 3-5) , and the proportion of truncated dystrophin mRNA accounted for approximately 40% when compared with the un-truncated form. Appreciably, dystrophin expression became rather uniform with approximately 85% normal levels in the diaphragm.
Higher doses of morpholinoE23 induced dystrophin expression in the cardiac muscle
More importantly, expression of dystrophin in the cardiac muscle was also dose dependent. Dystrophin expression was not clearly detectable in the cardiac muscle after treatment with morpholinoE23 at the doses of 0.15 g kg -1 or below by either immunohistochemistry, western blots or RT-PCR (Figures 3 and 4) . However, dystrophin expressing fibers, approximately 10%, were clearly shown when the dose reached 0.3 g kg -1 , although only a small proportion of the cardiomyocytes exhibited strong signal for dystrophin. Cardiomyocytes expressing high and low levels of dystrophin were distributed relatively evenly throughout the cardiac muscle. This pattern of distribution was different from that in skeletal muscles treated with lower doses of morpholinoE23, in which fibers expressing strong dystrophin frequently formed clusters of various sizes and intermingled with areas of fibers that completely lack detectable dystrophin. Similar to that observed in the skeletal muscles, dystrophin expression improved further with the increase in doses. A measure of (1) (2) (3) (4) (5) (6) , heart tissues (7-11) and cadiomyocytes (12) (13) (14) . 1, sample from control TA muscle; 12, freshly isolated cardiomyocytes without treatment; 2, 3, 7, 8 and 13, 2 days after 50 mg ml -1 morpholinoE23 treatment; 4, 5, 9, 10 and 14, 5 days after the treatment; 6 and 11, 7days after the treatment.
Dose-dependent restoration of dystrophin expression B Wu et al 1.5 g kg -1 morpholinoE23 induced dystrophin expression in 450% of the cardiomyocytes by immunohistochemistry, although most of the cells showed only weak signals for dystrophin with non-continuous membrane staining (Figures 3 and 4) . At the dose of 3 g kg -1 , morpholinoE23 induced dystrophin in nearly all cardiomyocytes, although variation in levels of expression remained clear. RT-PCR showed that mRNA with exon 23 skipped was approximately 30% of normal levels. This was supported by the levels of dystrophin protein restoration with western blot (Figure 4c ). These results suggest that effective exon skipping and restoration of dystrophin can be achieved in cardiac muscle, but requires higher doses of AON than in skeletal muscles. Correct skipping of the targeted exon 23 was confirmed by sequencing (data not shown). Dystrophin expression was also detected in smooth muscles in intestine, stomach and blood vessels in the lung ( Figure 5 ).
High doses of morpholinoE23 improved muscle pathology and serum creatine kinase level without toxicity
Immediately after injection of all doses of morpholinoE23, the mice woke up and started to move around, and the control mice was injected with saline only. All experimental mice ate and drank normally and the weight of treated mice remained similar to that of control mice (data not shown). There was no death in the mice treated with all doses of morpholinoE23. No increase in mononucleate infiltrates was observed and, similar to untreated controls, degenerating fibers in small focal areas were seen occasionally in all limb muscles of mice treated with any dose of morpholinoE23 (data not shown). As expected within the period of 2 weeks treatment, percentage of centrally nucleated fibers remained similar in all muscles of morpholinoE23-treated and control mdx mice. However, a considerable improvement was observed in the diaphragm of the mice treated with morpholinoE23 at the doses of 1.5 g kg -1 and higher. Severe muscle degeneration with areas of heavy infiltrates, frequently observed in the control mdx mice, was considerably reduced. The total number of CD3, CD4 and CD8 positive cells in the diaphragms of the mice treated with 3 g kg -1 morpholino was only 15 ( ± 6) compared with 154 (±36) in the control mice (per five microscopic fields under Â 200 magnification). The muscle fibers were more densely packed with less variation in size in the diaphragm of treated mice compared with the untreated control mice (Figure 6a) . The other evidence suggesting improvement of muscle pathology after morpholinoE23 treatment was the progressive reduction in serum creatine kinase levels as the doses of morpholinoE23 increased. Creatine kinase levels decreased after 0.15 g kg -1 morpholinoE23 treatment, although the difference was not significant. Substantial decrease of creatine kinase levels was observed in the mice treated with morpholinoE23 of 0.3 g kg -1 or higher when compared with those of the untreated mdx mice. Significant reduction was observed in the mice receiving 1.5 and 3 g kg -1 of morpholinoE23, although the levels were still higher than the normal ranges (Figure 6b ). Both liver and kidney were normal in histology without obvious inflammatory infiltrate and the levels of serum enzymes indicating the organ's functions remained within the normal ranges ( Figures  6a and b) .
Discussion
Recently, studies in our laboratory and other places have shown the great potential of using cationic peptides or polymers for enhanced delivery of morpholino and exon skipping effect. 21, 22 Systemic delivery of a morpholino conjugated with the peptide of (RXRRBR)2XB sequence were used for single intravenous injections into the mdx mice and body-wide muscles were examined 2 weeks later. Blue nuclear staining with DAPI. Note the relatively uniform appearance of dystrophin positive fibers in the diaphragm treated with 1.5 and 3 g kg -1 of morpholino.
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(R:arginine, X:6-aminohexanoic acid, and B:alanine) is able to restore dystrophin to almost normal levels in the cardiac and skeletal muscles in dystrophic mdx mouse. The treatment also increases muscle strength and prevents cardiac pump failure induced by dobutamine stress in vivo. However, the applicability of peptideconjugated morpholino for life-long treatment of muscular dystrophy remains to be determined. Specifically, the potential of immune response to the delivery enabling peptides needs to be assessed with long-term administration in animal models and ultimately by clinic trials. 21 More recently, we reported that a non-peptide cationic polymer, Octa-guanidine, also significantly improves morpholino-mediated exon skipping and dystrophin expression in both cardiac and skeletal muscles, resulting in amelioration in pathology of dystrophic mdx mice. 22 However, considerable increase in toxicity is expected when the cationic polymers are delivered systemically, although no clear toxicity is observed at the reported doses for a relatively short time period. Thus, cationic polymer-modified morpholinos can be used for clinical trials only when their acute and chronic toxicity, such as LD50 (dosage leading to 50% death) and long-term effect to vital organs, are determined. Therefore, alternatives for improving antisense effect with higher safety margin need to be explored.
In this study, we investigate the potential of unmodified morpholino for exon skipping in cardiomyoblasts and cardiomyocytes, and dose effect of morpholino on dystrophin expression in the dystrophic model of mdx mice. Our results clearly show that morpholino induces specific exon skipping effectively in both cardiomyoblasts and cardiomyocytes in culture. Exon skipping and dystrophin expression improve in all muscles as the dose of morpholino increases in vivo. Single dose of morpholino at 3 g kg -1 produces approximately 50 or 30% normal levels of dystrophin protein in skeletal and cardiac muscle, respectively. No toxicity is detected at the highest dosage. Thus, unmodified morpholino could be used to achieve therapeutic effect in dystrophic heart as well as in skeletal muscles if long-term safety is established.
Restoration of dystrophin expression in cardiac muscle becomes increasingly important for the life quality and longevity of DMD patients, as improved multidisciplinary patient care reduces their mortality from other causes. However, earlier studies have shown the difficulty to achieve effective exon skipping and dystrophin induction in the cardiac muscle with unmodified AONs including morpholino. 9, 10 The mechanism for a lower efficiency in exon skipping in cardiac muscle compared with skeletal muscles is not understood. One likely explanation is the less efficiency in delivery of unmodified oligomers systemically to cardiac muscle than to skeletal muscles in vivo, as delivery of morpholino is considered through a passive diffusion process rather than an active transportation. 23, 24 Thus, dystrophic muscle fibers are likely to be more permissible for the oligomers than those fibers with little damage or membrane permeabilization such as cardiomyocytes in the dystrophic mdx mice. This is consistent with the results from this study that efficiency in exon skipping is still lower in the cardiac muscle than in skeletal muscles even when high doses of the morpholino were used. Nevertheless, the results show that the charge-neutral morphoplino can enter the cardiac myocytes and induce effective and specific exon skipping, suggesting that degeneration process is not a prerequisite for effective rescue of dystrophin by unmodified morpholino. 21 Determination of effective dosage is a prerequisite for clinic applications of any potential drug. A clinic trial with morpholino for dystrophin exon 51 skipping is being conducted in UK for the treatment of DMD patients (personal communication). However, effective dose to be used for systemic administration has to be determined for individual antisense oligomer. Our earlier study suggests that therapeutic effect could be achieved in some skeletal muscles with dose of morpholino at approximately 60-80 mg kg -1 by regular injections in the mdx mice. 10 However, the same dose and treatment regiment fail to induce clearly detectable dystrophin Dose-dependent restoration of dystrophin expression B Wu et al expression in the cardiac muscle. 10 Similar dose effect of morpholino for dystrophin exon skipping has also been observed in the dystrophic dogs. 11 Thus, regular treatment of DMD with 80 mg kg -1 or below could rescue the dystrophic skeletal muscles, but is most likely insufficient for rescue of cardiac dysfunctions. This study shows that at the dose of 0.3 g kg -1 , morpholinoE23 can achieve approximately 5% dystrophin induction in heart muscles. Considering the likely variation in efficacy of antisense oligomers selected for targeting different dystrophin exons, this high dose of morpholino may well be required if the aim of exon skipping includes the rescue of cardiac muscle through a regiment of biweekly administration. However, one would argue that effective doses in human might be different from that in mice. Therefore, dose escalating clinic trials are critical.
In summary, our results showed that effective rescue of dystrophin in cardiac muscle as well as skeletal muscles can be achieved by unmodified morpholino. No toxicity is observed at any dosage. The high safety window together with the relatively long half-life (between 1 and 2 months) of the induced dystrophin provides prospect that unmodified morpholino can be used for long-term rescue of dystrophin for the treatment of DMD patients.
Materials and methods
Isolation, charactererization and culture of cells and tissues
Cardiomyoblasts and cardiomyocytes were isolated from the mdx mice aged 2 weeks. A portion of the left ventricle of mdx mice heart was used for cell isolation by collagenase digestion with Cellutron cardiomyocyte isolation kit (Cellutron Life Technology, Baltimore, MD, USA) and Liberase Blendzymes (Roche Applied Sciences, Indianapolis, IN, USA). [25] [26] [27] [28] The nature of cardiac myoblasts was confirmed by immunocytochemistry for Troponin I (Abacam, Cambridge, MA, USA). Cardiomyoblasts, cardiomyocytes and C2C12 myoblasts were grown in DMEM supplemented with 20% FBS (Gibco, Carlsbad, CA, USA), 2 mM L-glutamine (Gibco) and 100 units per ml of Penicillin/Streptomycin (Gibco). Cells were incubated at 37 1C with 10% CO 2 . Myoblasts were plated into six-well culture plates at 2 Â 10 5 cells per well and allowed to reach 70-80% confluence. The appropriate amount of morpholinoE23 was then added into the media (without transfection reagent). For delivery of morpholinoE23 to cardiomyocytes, the oligomers were mixed with the cells immediately after the isolation. For ex vivo culture, TA muscles and hearts were quickly removed from the mice after euthanasia. The pieces of the ventricular wall or TA (B6 mm 2 , 3-3.5 mm thick) were then placed on the Millicell culture plate inserts (0.4 mM Pore Size, Millipore, Billerica, MA, USA) and cultured in the same media as described above at 37 1C for 24 h. MorhplinoE23 was then added into the media (without transfection reagent).
Animals, oligonucleotides and delivery methods
Five mdx mice aged 4-5 weeks were used in each group. The antisense phosphorodiamidate morpholino oligomer (morpholinoE23) (5 0 -GGCCAAACCTCG GCTTACCTGA AAT-3 0 ) against the boundary sequences of exon and intron 23 of dystrophin gene is used. MorpholinoE23 tagged with fluorescein isothiocyanate was also used. MorpholinoE23 was prepared in 100 ml saline and administrated by retraorbital injections.
Mice were killed at desired time points, and muscles were snap frozen in liquid nitrogen-cooled isopentane 
Antibodies and immunohistochemistry
Sections of 6 mm were cut from at least two-thirds of muscle length of TA, quadriceps, biceps and gastrocnemius at 100-mm intervals and at least 10 levels from all other muscles including heart, diaphragm, intercostals and abdominal muscles at 100-mm intervals. The intervening muscle sections were collected either for western blot or RT-PCR analysis. The serial sections were stained with rabbit polyclonal antibody P7 against dystrophin. The primary antibody was detected by goat-anti-rabbit IgGs Alexa 594 (Invitrogen, Eugene, OR, USA). Sections were also stained with hematoxylin and eosin for histological assessment. Fluorescein isothiocyanate-labeled monoclonal antibodies to mouse CD3, CD4 and CD8 (EBioscience, CA, USA) were used in combination for detection of lymphocyte infiltration in the diaphragm. The number of cells was counted in five microscopic fields under 200 times of magnification.
Protein extraction and western blot
The collected sections were ground into powder and lysed with 200 ml protein extraction buffer as described earlier. 21, 22 The protein concentration was quantified by ), alanine transaminase (ALT) (U per 100 ml), alkaline phosphatase (ALP) (U per 100 ml) and gamma-glutamyltransferase (GGT) (U l -1 ). Significant reduction in creatine kinase levels was observed in the 1.5, 3 g kg -1 morpholinoE23-treated mdx mice compared with untreated mdx mice (n ¼ 5, two-tailed t-test, *Po0.05). No significant differences were detected for other serum components between the two groups of mdx mice except for ALT, which showed elevated levels in the untreated mice. Mdx mice were intravenously treated with a series of doses of 0.03 g kg -1 up to 3 g kg -1 of morpholinoE23.
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Protein Assay Kit (BioRad, Hercules, CA, USA). Proteins from normal C57BL6 mice (positive controls) and from treated mdx mice were loaded onto a 6% polyacrylamide gel containing 0.2% SDS and 10% glycerol. Samples were electrophoresed overnight at 10 mA at 4 1C and blotted onto nitrocellulose membrane overnight at 300 mA. The membrane was then washed and blocked with 5% skimmed milk and probed with monoclonal antibody NCL-DYS1 against dystrophin rod domain (Vector Labs, Burlingame, CA, USA) overnight. The bound primary antibody was detected by horseradish peroxidase-conjugated goat anti-mouse IgG and ECL Western Blotting Analysis System (Perkin Elmer, Waltham, MA, USA). The intensity of the bands obtained from the oligomertreated mdx muscles was measured and compared with that from normal muscles of C57BL6 mice (NIH ImageJ 1.42 software).
RNA extraction and RT-PCR
The collected Sections were homogenized in TRIzol (Invitrogen) by using an Ultra-Turrax homogenizer (Janke and Kunkel, Staufen, Germany). Total RNA was then extracted and 100 ng of RNA template was used for a 50- 
Measurement of serum creatine kinase and other components
Mouse blood was taken immediately after cervical dislocation and centrifuged at 1500 r.p.m. for 3 min. Serum was separated and stored at À80 1C. The level of serum components was determined by Charles Riverside Laboratories, USA.
